covered thoroughly. Carter you, financials very Thank Carter. the
say distribution, R&D the Q&A. about product and only talk couple before I we'll and I'll financials words facility, sales about commercial a go So then of high-level the to
growing. are revenues Our
is pipeline R&D the and R&D growing. in investment Our
than NASDAQ are stable fundamentals getting merger closer acquisition. or strong Our to and more the we ever, are
best time $XX year us were launch enough [ we to Last million We X companies generated agreement million multiple a where dip distribution was came ever. other going the we $XX revenues. to selling start to was quarters, between quarters sales was the were had The did still products, because up thought our the product revenues. switching is year and ] with have $XX X We most Lannett. generated Elite's give companies million. and at by in terminated last In both. Elite DEA finish experts including in one the major not This Lannett and we've in ago. between when That revenues
revenues, target IR definitely of million. market on in than of to share and serious year Lannett. noteworthy Amphetamine today, are achievement. market And the a That ER a another is We larger north recommend record-breaking we $XX
of needle year XXXX. Prasco in approved and XXXX of and move expectation this agreement as implementation will my products the that It beyond. R&D in January calendar and trend X, the With continue is XXXX XXXX,
is Our XXXX business XXXX. great looking model and for
acting alone in XXXX, be and north Elite's under that. IR year just to these If that million. be the products this years way year The at last to you were of Amphetamine products Elite $XX be lot are product X December, will continue a currently revenues, The look January largest largest and next our are bringing label. than ER, gonna that through
a contracts challenge. maintain our have place, expect share. We double-digit Managing and the market in DEA has been we to quarter
product, relaxant, hypertension and of X, for However, rest products weight Loxapine shortage the Phendimetrazine manage Loxapine of XXXX. to Isradipine, and this Elite The agitation and schizophrenia Phentermine loss April a and product. products, very under and demand. are on the list as well in been date. portfolio Amphetamine contains bariatric sold Elite's commercial Trimipramine, remains Dantrolene through challenge a has IR FDA antidepressant being as our label is muscle able both products, are to
product has job And our any frankly, done. Perrigo is our doing a of selling ever partners than better at
OxyContin this partnership With products management, and with issues not We future. antibiotic, OxyContin, time. to have not any opioid, sold because we with and products problems [indiscernible] being are that We lot have also plans at there the are pain at an near Doxycycline do that we and these X Praxgen have a in a opioid [indiscernible]. a One, the and time, not with two, product. resolved the is and an it's this of haven't associated sell
As packaging, sales far space testing, as and more holding facility and more requires and more the and equipment. in employees is more manufacturing, testing and distribution increase concerned, storage
with the have pieces upgraded sales have units. to and we So purchased several equipment backup keep to of up
for size now. facility mind a of I you been As my discussed have while and the capacity on our have with before,
demands Even for We is a the running space the today though supply It's customers' the day shift our half don't by substance. week. to probably facility a we every controlled and can store. have on
you impact explain you your them them So the in and and make and ingredients, bottling and buckets, come materials inactive me When put within space capsules. pharmaceutical takes And ingredients and and in package to capsules them. mix they you let tablets tablets you them, raw pharmaceutical buy bottles, blend the the and then that. massive and active you compared the and bottle. IPI, that the amount The API
are these them substances, vaults. because you put Now have controlled to in
an becoming need, make, you more and is the more space that issue. vault you So the
them them making to were others. and and we Before shipping Lannett's
resolve our it's distribution, we problem our very that soon. it's facility, to Now need and
catastrophe to a manufacturing be manufacturing the of warehouse or where duplicate you So better a blending and options for you and exploring equipment There'll we is side, continuity we what is rent fit I've and your on facility. have business. that as site capacity where if continue and been business facility and have storage another into and And you. One current buy leverages can on updated personnel that that before. there have tremendous you a in a option packaging has lines have advantage have you one to
the it run the also to But to to And expensive very disadvantage very of it extended-release duplicate trials equipment. is transfer being clinical products. has the expensive
CBEXX only release the transfer they do not lot, few the on all instant require doesn't it's you a equivalent retrofitted, transfer to where So the that option similar, manufacture to takes be release still somewhere money another else, a process would require IR something products, instant all place it. and it get plan, of equipment do trials, a just lot of buy cost facility, It's another to a and that it duplicate manufacture stability, and it because but products costs you clinical so months, file much. The internal.
But that.
million. cost So for Option option to to $XX estimate do. million option X X the and between X, what is we decided was $XX
to the company. a going since is me it part be walk that through So let you of
you feet. the in is the is and you the that's get Our one of all you package of manufacturing. trucks facility put them. APIs And where is middle the all facility The where where product is and the side, facing manufacturing facility square there, facility your right enter do you come the side out. are from you components the facility of about and XX,XXX But the IPIG, enter the on current
inexpensive be storage company product, manufacturing to the So and final for has in it space out for packaging take facility all out we thought the future. package us to where what and us which and will expanding enough help the release and that be and the that I if for take is will the give vaults a the to part do a facility finished move
And have now of have packaging a we instead X capacity. we we have so lines new where unlimited facility X,
a noncontrol have larger stories the much for have vault. we We And substances.
Managements to the enough Long continue and facility, to the from They the actually facility was were staff have on retain keep and a that Elite. happy which of they to So will our staff. next can we door, signed work letter lucky current Monday. just the can quit and on the are is XXth mile staff. report in don't North we an and find means somebody got Whale I about -- working cost $X.X have we they with, move and manufacturing decided of gets of Island, Philadelphia that to on the else Board only Directors about next option intent And so door of starting the eye million. am within a I to go to the approval
of We by we are expect mid move into next and negotiating middle the facility. that the details, will new I in year, the
products. have we So our
sales today's selling We have products revenues. generating and and our marketing that's the
the be the have up to go facility years, to We X next for good set least. at
need happened growing business the share affect case the keep pipeline company. Now and that our not the we where reduced, gets enters does the in order market somebody and to in anything
In marketing increase comes fact, products, to in sales other we and want R&D and where in. that's introducing share our by
continue We in development. invest to will product definitely
Our new line to but goal the is diversify to market. made products our is product commercialize nothing Commercial R&D a line it an portfolio. that competitive and
thinking the are ones all that's product the future. it market in They extension So because the is is the the the bring an one the are to R&D is. today, I'm the who always to bringing going commercial they revenues that's R&D are and revenues
do. R&D all is the right So to have into the thing investing profits we
It's we recession, and get trials you sequences with let through file means you I are me you clinical and gateway. the update when is Once you. After here. point from FDA for the electronic it at say, ANDA do the the do okay, what done look and have that to as we in So can an send it you ANDA you compile an the the where the in so an got the on all them ANDA, happens the FDA, will to to walk FDA's have receive you and all filed we that, everything parts through queue.
So we and components there. covered Then parts acknowledge they the it at make of properly we critical XX look that that sure that that order in received days everything linked the the it's themselves you of all are ANDA it. to are that give
X, clinical okay. module controls, for is the for And manufacturing drug you through is Module Module X trials. ANDA and have the the for is chemistry product. X quarts, Module drug X clinical also X the X have where trials. and substance
okay? look we at did the waited and days we So all days, time till say, That's after an approval they least PDUFA accepted announce not So the mover. because will they announcement last then. The this same will now components to FDA, when did has receive filed been we about days, till happen needle for and second XX be the make it these is at or that with thing from this FDA the opioid XX ANDA going fine, the filing and by we date accepted review. it's
As accepted we hear soon December as been from the it has in that review. for FDA
me not and end and is what the they prosecution say, issue eligible. Gap] they So testing right? this receive this, here, We fix the it when it all the review, for examination announcement, accept then will of process more documents, sent do an [Audio evaluation does FDA start
entire throughout that months. do the You XX
tell months we go FDA you then guys, received not. we hey, response into and file, from for when a XX So banking or we don't
communicating actually are basis, We on right? them regular a with
and will know prosecution been year. you fourth accepted And X I review make has that month have So ANDAs FDA. let it under that we that have next the the been this by one accepted for today, for so review for that will
the ANDA we with us. And has ANDAs submitted, been One is that of dopamine back that the FDA corresponding agonist. forth and
micro During the ANDA, that not ANDA found lab they the adequate. evaluation of the that did on the microbiological was testing
So a they sent us note.
ahead cross-cuted, things in change ANDA has cannot been the you it. it. and while That's go Now
coming of You the the end have to wait till month.
change we they the tell had will weeks. was our passes October, refile GDUFA probably which doing go X lab, So ahead where wait that, it within and and until us, to date,
ANDA, ANDA, product in second The very because is FDA is the shortage. that the interested on antimetabolite that product
it approved which to is So very with the by before. February or us working get that closely the is ensure does GDUFA date, FDA
the is ANDA one received third its opioid. The acceptance for we the
will my to be that Amphetamine what study us IR X to for, been largest we that more questions. We X or the of to than so month another yet. on a did month we total a going the are haven't guidance are will of expect at expect them, And in hopefully ER And next and GDUFA changers. the do. FDA, expecting and fourth the most they which that product they products be bigger And ones pilots response start of than am I pilot gotten XXXX. the file X and XXXX study ended opioid have DV we is X, X in much market, game have what that I from months. run asking them okay? going we that because we're And that's to opinion, product that and mover. after then. Other couple which ANDA, that they are the only are the September in the the focus while pending of the needle It's on I we're the date for give is going be These
the lot forward, for what that effort we by effort that of Well, is products. about we on actives, of going are In of Elizabeth an way takes XXX, pay. after earlier, example the is the work rest the work, at work And and and had I larger are them the small alluding preliminary a products no we like in work products, Next on product. small more XX on product bringing It company. was lot products going were products. to fillers. larger that It takes is XX% the Out company to I've the that to the a decision money on dopamine a the agonist of very but a longer facility. to XXX I small made of small were mean really
single every to going So a billion-dollar large select going you to are is product forward, be going product.
you have tablets, have release, I'll market X And that. to be on And either and that that $X patent have technology, of they above. be these fits billion X are to the instant patent -- beyond identified capsules, very products off selected for every on that we couple is for dated within These or starting of good a X more market. each will generation. release. we're keep on still are soon updated going them And on That that extended other are need a the than be we our or products years, a products either we working next all of one and
is it wrap around finally. up, extremely is this The turning exciting. company To
company We distribution. own and are becoming a fully functional with sales pharmaceutical having our
distribution and approvals plans, are our I'll product sales revenues. obtaining on ANDAs, and go that, new increasing and filing Q&A. growth our We expanding organization With to executing our
out always, grouped As read my when loud of them I presentation, to that the answer at And sent did know incorporate the questions them needed. answer called but she other to you've of submitted of look address quite I'll Dianne, and I me, for some me some a and bit out, to answer. you she questions that
